Medicus Pharma Ltd. (MDCX)
NASDAQ: MDCX · Real-Time Price · USD
3.400
+0.020 (0.59%)
At close: Jul 7, 2025, 4:00 PM
3.590
+0.190 (5.59%)
Pre-market: Jul 8, 2025, 8:15 AM EDT
Company Description
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets.
It develops SkinJect for the treatment of basal cell carcinoma. The company was founded in 2015 and is headquartered in Toronto, Canada.
Medicus Pharma Ltd.
| Country | Canada |
| Founded | 2008 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| CEO | Raza Bokhari |
Contact Details
Address: One First Canadian Place, Suite 3400 Toronto, ON M5X 1A4 Canada | |
| Website | medicuspharma.com |
Stock Details
| Ticker Symbol | MDCX |
| Exchange | NASDAQ |
| Reporting Currency | USD |
| CIK Code | 0001997296 |
| ISIN Number | CA58471K2020 |
| Employer ID | 98-1778211 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Raza Bokhari M.B.A., M.D., MBA | Chief Executive Officer and Executive Chairman |
| James P. Quinlan C.P.A. | Chief Financial Officer |
| Dr. Edward J. Brennan Jr., F.A.C.S., FACS, M.D. | Chief Scientific Officer and Head of Research & Development Program |
| Carolyn Bonner | President |
| Anna Baran-Djokovic J.D. | Senior Vice President of Investor Relations |
| Viktoriia Slepeniuk | Senior Vice President of Public Relations |
| Dr. Faisal Mehmud M.D. | Chief Medical Officer |
| Maryann Adesso | Chief of Staff and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 3, 2025 | 424B3 | Prospectus |
| Jul 3, 2025 | 424B3 | Prospectus |
| Jul 3, 2025 | 253G2 | Acc-no: 0001493152-21-027927 (33 Act) |
| Jul 3, 2025 | 424B3 | Prospectus |
| Jul 3, 2025 | 8-K/A | [Amend] Current report |
| Jun 30, 2025 | ARS | Filing |
| Jun 30, 2025 | DEF 14A | Other definitive proxy statements |
| Jun 30, 2025 | 424B3 | Prospectus |
| Jun 30, 2025 | 424B3 | Prospectus |
| Jun 30, 2025 | 253G2 | Acc-no: 0001493152-21-027927 (33 Act) |